What question did this study set out to answer?

This study aims to evaluate the real-world effectiveness of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PS5-05-17: Real-world effectiveness of Trastuzumab Deruxtecan in HER2-low Metastatic breast cancer: a single-center retrospective study

View Full Paper

Ask AI

Bookmark

Authors

YCY. ChenPeking University GSG. SongPeking University HLH. LiPeking University

Discussion

Member takes

Implication

A retrospective study reveals trastuzumab deruxtecan's modest effectiveness in HER2-low breast cancer, highlighting the need for earlier intervention.

Key Points

This study aims to evaluate the real-world effectiveness of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer.
Conducted a retrospective analysis of 81 patients with HER2-low advanced breast cancer.
Utilized clinical data from Peking University Cancer Hospital.
Assessed radiologic responses and progression-free survival (PFS) of patients after treatment with T-Dxd.
Median PFS for all patients was 6.0 months, with HR+ disease showing a slightly better PFS of 6.7 months compared to 3.4 months in TNBC.
Patients with up-regulated HER2 expression had a longer PFS of 7.0 months.
The presence of active brain metastases did not significantly alter PFS, maintaining similar values around 6 months.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6996a8a9ecb39a600b3ef95c https://doi.org/10.1158/1557-3265.sabcs25-ps5-05-17

View Full Paper

Ask AI

Bookmark

Implication

A retrospective study reveals trastuzumab deruxtecan's modest effectiveness in HER2-low breast cancer, highlighting the need for earlier intervention.

Abstract PS5-05-17: Real-world effectiveness of Trastuzumab Deruxtecan in HER2-low Metastatic breast cancer: a single-center retrospective study

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS5-05-17: Real-world effectiveness of Trastuzumab Deruxtecan in HER2-low Metastatic breast cancer: a single-center retrospective study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider